CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 71 enrolled
Drug / intervention
fruquintinib +1 moredrug
Likely dose
fruquintinib 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02196688
NCT02196688Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Colorectal Cancer as 3rd or Above Therapy

Hutchison Medipharma Limited·interventional·Posted Jul 22, 2014·Updated Jun 16, 2020

In Brief

A Phase 2 clinical trial evaluating fruquintinib and placebo for Colorectal Cancer. Completed, enrolled 71 participants across 5 sites.

Detailed Summary

Fruquintinib administered at 5mg once daily in 4 weeks treatment cycle (three weeks on and one week off) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with advanced Colorectal Cancer (CRC) in Phase Ib study. This study is aimed to evaluate the efficacy and safety of Fruquintinib in the treatment of patients with metastatic CRC who have progressed after metastatic CRC second line or above standard chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesChina
CollaboratorsFudan University, Sun Yat-sen University

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 22, 2014
Enrollment StartApr 1, 2014
Primary CompletionApr 1, 2015
Study CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 11.9 years ago

Interventions

fruquintinibdrug

fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off

placebodrug

Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off